[{"id":"15ea0b15-7362-42f9-a5c9-83b6fa5b6dd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451982","created_at":"2021-01-18T11:45:29.420Z","updated_at":"2025-02-25T14:35:37.102Z","phase":"Phase 2","brief_title":"Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas","source_id_and_acronym":"NCT02451982","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • PD-1 • TNFRSF9 • GZMB • IL17A","pipe":"","alterations":" ","tags":["CD8 • PD-1 • TNFRSF9 • GZMB • IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cyclophosphamide • BMS-986253 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • cyclophosphamide intravenous • urelumab (BMS-663513)"],"overall_status":"Recruiting","enrollment":" Enrollment 76","initiation":"Initiation: 03/28/2016","start_date":" 03/28/2016","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2024-12-06"},{"id":"f072507e-9a2d-436e-a0d2-a7669c7954ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT02658981","created_at":"2021-01-18T12:57:12.241Z","updated_at":"2025-02-25T14:36:06.324Z","phase":"Phase 1","brief_title":"Anti-LAG-3 Alone \u0026 in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)","source_id_and_acronym":"NCT02658981","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016) • urelumab (BMS-663513)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 08/24/2016","start_date":" 08/24/2016","primary_txt":" Primary completion: 04/30/2022","primary_completion_date":" 04/30/2022","study_txt":" Completion: 10/03/2023","study_completion_date":" 10/03/2023","last_update_posted":"2023-10-06"},{"id":"ed108878-46a5-4e3a-93b2-f64236ea023a","acronym":"C4-MOSART","url":"https://clinicaltrials.gov/study/NCT03431948","created_at":"2021-01-18T16:55:43.382Z","updated_at":"2025-02-25T14:38:06.135Z","phase":"Phase 1","brief_title":"Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer","source_id_and_acronym":"NCT03431948 - C4-MOSART","lead_sponsor":"University of Chicago","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cabiralizumab (BMS-986227) • urelumab (BMS-663513)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/15/2018","start_date":" 03/15/2018","primary_txt":" Primary completion: 02/29/2020","primary_completion_date":" 02/29/2020","study_txt":" Completion: 04/11/2022","study_completion_date":" 04/11/2022","last_update_posted":"2023-02-16"},{"id":"3a4bddbb-6cf6-4ec6-98b4-5a4617c30e37","acronym":"","url":"https://clinicaltrials.gov/study/NCT02652455","created_at":"2021-01-18T12:54:49.210Z","updated_at":"2025-02-25T14:36:05.082Z","phase":"Phase 1","brief_title":"Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma","source_id_and_acronym":"NCT02652455","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous • urelumab (BMS-663513)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 03/08/2016","start_date":" 03/08/2016","primary_txt":" Primary completion: 08/30/2020","primary_completion_date":" 08/30/2020","study_txt":" Completion: 08/30/2020","study_completion_date":" 08/30/2020","last_update_posted":"2023-01-19"},{"id":"968607af-4d9f-4e30-8a68-30bb86958c13","acronym":"INTRUST","url":"https://clinicaltrials.gov/study/NCT03792724","created_at":"2021-01-18T18:45:05.911Z","updated_at":"2024-07-02T16:37:04.299Z","phase":"Phase 1/2","brief_title":"Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors","source_id_and_acronym":"NCT03792724 - INTRUST","lead_sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","biomarkers":" PD-L1 • MSI","pipe":"","alterations":" ","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • urelumab (BMS-663513)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 01/30/2019","start_date":" 01/30/2019","primary_txt":" Primary completion: 01/30/2023","primary_completion_date":" 01/30/2023","study_txt":" Completion: 01/30/2023","study_completion_date":" 01/30/2023","last_update_posted":"2019-01-03"}]